Every announcement Biocon has filed with the exchanges that we have reported, newest first. Each story links the original filing.
Price
₹409.4
Market Cap
₹66,719.68 Cr
Revenue TTM
₹17,321.10 Cr
P/E (TTM)
134.71×
Sector 46.94×
Reference data from Trendlyne, as of the most recent story. Not a valuation or a recommendation.
Biocon Biologics Receives Japan MHLW Approval for Pegfilgrastim Biosimilar Marketing
Biocon Biologics receives Japan MHLW marketing approval for its Pegfilgrastim biosimilar. This oncology product strengthens Biocon's ₹17,321 Cr TTM r…
Biocon Ltd Launches Yesafili Biosimilar in US Market to Address USD 5.89 Billion Opportunity
Biocon Ltd announces the US commercial launch of Yesafili, an interchangeable biosimilar to Eylea. The product targets a US market with 19.8 million …
Track Biocon in real time
ALFA Finder watches NSE & BSE filings 24/7 and alerts you the moment Biocon files something material.
Start Free — 15-day trial